The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells
✍ Scribed by Tuure Kinnunen; Cecile Buhot; Ale Närvänen; Marja Rytkönen-Nissinen; Soili Saarelainen; Sandra Pouvelle-Moratille; Jaakko Rautiainen; Antti Taivainen; Bernard Maillère; Rauno Mäntyjärvi; Tuomas Virtanen
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 351 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We have proposed earlier that the poor capacity of the lipocalin allergen Bos d 2 to stimulate highly allergic subjects' peripheral blood mononuclear cells could be ascribed to endogenouslipocalins and could be related to the allergenic potential of the molecule. Here, we have characterized the proliferative and cytokine responses of human T cell clones against the immunodominant epitope of Bos d 2. We observed, for clone F1‐9, that a substitution of aspartic acid for asparagine in the core region of the epitope increased the stimulatory capacity of the peptide about 100‐foldin comparison with the natural peptide. For clone K3‐2, from a different patient, the substitution of lysine for glutamine or isoleucine for leucine in the core region resulted in about 30‐fold and10‐fold increases in the stimulatory capacity of the peptides, respectively. The clones also recognized self‐protein‐derived peptides but not the peptides derived from other lipocalins. We suggest that the poor recognition of the immunodominant epitope of Bos d 2 can be a factor accounting for Bos d 2‐allergic subjects' weak cellular responses. Suboptimal recognition of self and allergen epitopesby T cells may be of significance for the allergenicity of proteins.